deltatrials
Unknown PHASE2 INTERVENTIONAL 2-arm NCT04089150

MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease (MASTERPLAN)

MASTERPLAN: A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease

Sponsor: Australasian Gastro-Intestinal Trials Group

Conditions Pancreatic Cancer
Interventions Gemcitabine + Capecitabine Gemcitabine + Nab-paclitaxel Pancreatoduodenectomy (Whipple procedure) Stereotactic Radiotherapy (SBRT) mFOLFIRINOX
Updated 6 times since 2019 Last updated: Oct 15, 2021 Started: Oct 1, 2019 Primary completion: May 31, 2023 Completion: Aug 30, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Pancreatic Cancer and is currently ongoing. Australasian Gastro-Intestinal Trials Group leads this study, which shows 6 recorded versions since 2019 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Oct 2019 – ~Jan 2021 · 15 months · monthly snapshotNot Yet Recruiting~Jan 2021 – ~Nov 2021 · 10 months · monthly snapshotNot Yet Recruiting~Nov 2021 – ~Nov 2023 · 24 months · monthly snapshotRecruiting~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshotUnknown Status~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshotUnknown

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Unknown PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Unknown PHASE2

    Status: Unknown Status → Unknown

  3. Nov 2023 — Jul 2024 [monthly]

    Unknown Status PHASE2

    Status: Recruiting → Unknown Status

  4. Nov 2021 — Nov 2023 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  5. Jan 2021 — Nov 2021 [monthly]

    Not Yet Recruiting PHASE2

▶ Show 1 earlier version

  1. Oct 2019 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Australasian Gastro-Intestinal Trials Group
  • Australian Government Department of Health and Ageing
  • Trans Tasman Radiation Oncology Group
Data source: Australasian Gastro-Intestinal Trials Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations